Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.

Carlos Fernández-Martos,Isidro Machado,Carles Pericay,Nuria Rodríguez Salas,Jaime Feliu Batlle,Sanne ten Hoorn,Louis Vermeulen,Ferran Losa,Rocio Garcia-Carbonero,Vicente Alonso,Ruth Vera,Javier Gallego,Jaume Capdevila,Antonieta Salud,Miguel Nogué,Joan Maurel,Laura Layos,Clara Montagut,Xabier García-Albéniz

Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.

2020

Carlos Fernández-Martos
Isidro Machado
Carles Pericay
Nuria Rodríguez Salas
Jaime Feliu Batlle
Sanne ten Hoorn
Louis Vermeulen
Ferran Losa
Rocio Garcia-Carbonero
Vicente Alonso
Ruth Vera
Javier Gallego
Jaume Capdevila
Antonieta Salud
Miguel Nogué
Joan Maurel
Laura Layos
Clara Montagut
Xabier García-Albéniz

4102Background: Neoadjuvant chemotherapy (CT) followed by CRT and TME is a treatment option for clinically staged HRRC. The goal of the GEMCAD 1402 trial was to evaluate the benefit of adding an an...

Keywords:

Induction chemotherapy
Urology
Aflibercept
Total mesorectal excision
in patient
Pathology
Rectal Adenocarcinoma
Chemoradiotherapy
Medicine
treatment options
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations